Arriani Pharmaceuticals S.A. is proud to announce the commercial availability of SenTraGor™ reagent , a breakthrough technolo ... gy that will boost the understanding of senescent cells role in age-related disorders. SenTraGor™ reagent is a unique compound that detects senescent cells in every biological sample with high specificity and sensitivity , through an antibody-enhanced technology. Behind this breakthrough technology are Professors Vassilis Gorgoulis (National Kapodistrian University of Athens, Biomedical Research Foundation of the Academy of Athens, University of Manchester) and Paul Townsend (University of Manchester). SenTraGor™ reagent is the commercial name of GL13 compound, whose novelty and synthesis were published online in Ageing Cell on 17 November 2016, DOI: 10.1111/acel.12545 and has received a very warm welcome by the scientific community. There are numerous applications of this unique reagent and the methods of its utilization are through Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), Flow Cytometry Analysis (FACS), and additionally co-Immunohistochemistry (co-IHC) and co-Immunocytochemistry (co-ICC). Detailed, step-by-step protocols can be provided upon request at info@sentragortechnology.com There is also available a video presenting in detail the application of SenTraGor™ reagent through a standard Immunohistochemistry protocol. New methods for its numerous applications are under development for which detailed protocols will be provided. The unprecedented technology introduced with SenTraGor™ reagent opens new horizons to every scientist who studies or whishes to study senescence. The only thing that should be done is just to replace the primary antibody with SenTraGor™ reagent to observe senescent cells. read more